Biological Age Assessment

How would YOU like to make your patients YOUNGER!
Biological Age Assessment
Method
Participants were recruited by the Allicin Centre in 2011 by offering a free Biological Age test. This was per­formed using the CardioTrace technology to record a measurement of heart rate, arterial stiffness and blood oxygenation. A blood pressure measurement was also taken with a brief medical history. Patients showing a higher biological age than their actual age were offered the chance to take up to 6 capsules of Heartfast in one dose and to return within 1 hour to undergo another test. The table below shows the results of these volunteer evaluations.
CardioTrace is a painless, non invasive procedure. An infrared sensor is simply clipped to the patient’s finger and infrared light is passed through it. The sensor automatically scans, collects and analyses the data from the sensor and, from the amassed information, can determine the stiffness of a patient’s artery.
It is able to do this by ascertaining the patient’s BMI (obtained by placing data, including height, sex, race, weight and age, into the machine beforehand) as well as their heart rate, blood speed (hence viscosity) and finally the arterial stiffness index. Furthermore, CardioTrace holds patients’ data obtained by previous examinations so that a trend analysis may be calculated and therefore this data is clinically validated.
Following data collection, the software will ascertain the age of the patient’s arteries. This vascular age can be compared to your own age to see how your cardiovascular system is ageing in relation to your physical or chronological age. Patients vary considerably but in our small survey at the CAM show, over 53% of volunteers showed an increased biological age with arterial stiffness. CardioTrace is a world leader in Pulse Wave Technology which puts this valuable test in the hands of primary care screeners and medical professionals. Central Aortic Systolic Pressure (CASP) is one of the most powerful, early predictors of cardiovascular risk. Safe and non invasive pulse wave analysis applies the principles of sonar to assess the pliability of the vascular tree, including the major central vessels as well as the smaller peripheral vessels. Central aortic vascular compliance, or lack of it, is a key indicator of vascular health status.
Results and Discussion
All volunteers, not taking pharmaceutical medication for pre-existing heart disease, reduced their biological age to significantly “younger” than their actual age. All volunteers showed a significant fall in arterial wall stiffness or Stiffness Index – this indicates a reduction in cardiovascular risk by improving the quality of blood leaving the heart and travelling the entire length of the circulatory system as measurements were taken at the farthest point from the heart. Two volunteers showed an increase in Biological Age but both were taking several pharmaceutical drugs and so measurements are much less meaningful as the CV system is carefully controlled by these medications.
Cardiovascular Disease still claims more lives each year than the next 5 leading causes of death combined, which are cancer, chronic lower respiratory diseases, accidents, diabetes mellitus, influenza and pneumonia. Consequently any proven intervention is likely to contribute to a reduction in CVD risk.
 

Stiffness Index and Biological Age measurements

Volunteer SI Before SI After Bio age Before Bio age After

1

11.0

9.0

58

49

2

11.4

9.5

61

52

3

10.3

9.5

58

55

4

8.1

6.9

39

34

5

10.4

8.3

52

43

6

13.1

10.7

75

65

7

11.9

10.0

67

58

8

10.9

9.2

57

49

9

10.6

8.4

58

48

10

11.8

9.5

63

52

11

10.9

9.6

53

47

12

11.8

9.8

51

44

13

12.6

12.6

75

77*

14

10.9

11.4

69

72


Whilst this will always include phar­ma­ceu­ti­cal med­ica­tions for those already diag­nosed, in our sur­vey only a tiny per­cent­age of those tested had been diag­nosed even though from our obser­va­tions those undi­ag­nosed did show some degree of risk. This could have seri­ous impli­ca­tions for the long-term health of our population.

Clearly the Heart­fast for­mu­la­tion has the capa­bil­ity of improv­ing a patient’s rel­a­tive risk of CVD by reduc­ing their bio­log­i­cal age and arte­r­ial wall stiff­ness. All the ingre­di­ents are well known and gen­er­ally con­sid­ered as safe. With an extremely low propen­sity for side-effects, this treat­ment could be safely admin­is­tered to a large pro­por­tion of the pop­u­la­tion and con­tribute to an improve­ment in car­dio­vas­cu­lar health and well-being.

*Tak­ing a num­ber of phar­ma­ceu­ti­cal agents for pre-existing heart disease